Ultragenyx Pharmaceutical Inc. $RARE Shares Purchased by Profund Advisors LLC

Posted by Stanley Muller on May 21st, 2026

Profund Advisors LLC lifted its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Free Report) by 75.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 56,624 shares of the biopharmaceutical company’s stock after purchasing an additional 24,360 shares during the quarter. Profund Advisors LLC’s holdings in Ultragenyx Pharmaceutical were worth $1,302,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Ultragenyx Pharmaceutical by 14.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 232,360 shares of the biopharmaceutical company’s stock valued at $8,414,000 after purchasing an additional 29,984 shares in the last quarter. Creative Planning purchased a new stake in shares of Ultragenyx Pharmaceutical during the second quarter valued at $454,000. American Century Companies Inc. purchased a new stake in shares of Ultragenyx Pharmaceutical during the second quarter valued at $366,000. M&T Bank Corp increased its position in shares of Ultragenyx Pharmaceutical by 19.7% in the 2nd quarter. M&T Bank Corp now owns 7,232 shares of the biopharmaceutical company’s stock valued at $263,000 after acquiring an additional 1,192 shares during the period. Finally, Amundi increased its position in shares of Ultragenyx Pharmaceutical by 1,560.4% in the 2nd quarter. Amundi now owns 99,161 shares of the biopharmaceutical company’s stock valued at $3,913,000 after acquiring an additional 93,189 shares during the period. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have commented on RARE shares. Barclays lowered their price target on Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating for the company in a research report on Wednesday, April 29th. JPMorgan Chase & Co. cut their price objective on Ultragenyx Pharmaceutical from $120.00 to $74.00 and set an “overweight” rating on the stock in a report on Thursday, March 12th. Morgan Stanley raised their price objective on Ultragenyx Pharmaceutical from $50.00 to $67.00 and gave the stock an “overweight” rating in a research note on Thursday, April 16th. The Goldman Sachs Group downgraded Ultragenyx Pharmaceutical from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $61.00 to $25.00 in a report on Tuesday, March 24th. Finally, Wedbush dropped their target price on Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $60.41.

Get Our Latest Analysis on Ultragenyx Pharmaceutical

Insider Activity at Ultragenyx Pharmaceutical

In related news, EVP Karah Herdman Parschauer sold 8,135 shares of the firm’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $22.80, for a total transaction of $185,478.00. Following the sale, the executive vice president owned 76,346 shares in the company, valued at approximately $1,740,688.80. This trade represents a 9.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Howard Horn sold 4,683 shares of Ultragenyx Pharmaceutical stock in a transaction on Friday, May 1st. The shares were sold at an average price of $24.90, for a total transaction of $116,606.70. Following the completion of the transaction, the chief financial officer directly owned 110,342 shares of the company’s stock, valued at $2,747,515.80. The trade was a 4.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 117,262 shares of company stock valued at $2,687,403 in the last quarter. 5.20% of the stock is currently owned by insiders.

Ultragenyx Pharmaceutical Trading Up 4.1%

Shares of NASDAQ:RARE opened at $23.37 on Thursday. Ultragenyx Pharmaceutical Inc. has a 12-month low of $18.29 and a 12-month high of $42.37. The business has a 50 day moving average of $23.18 and a two-hundred day moving average of $26.22. The company has a market capitalization of $2.30 billion, a PE ratio of -3.82 and a beta of 0.39.

Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) EPS for the quarter, missing analysts’ consensus estimates of ($1.49) by ($0.35). The firm had revenue of $136.00 million for the quarter, compared to analyst estimates of $158.19 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 91.03%.Ultragenyx Pharmaceutical’s revenue for the quarter was down 2.2% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.57) EPS. Equities research analysts predict that Ultragenyx Pharmaceutical Inc. will post -4.63 earnings per share for the current fiscal year.

Ultragenyx Pharmaceutical Profile

(Free Report)

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.